The better benefit of immunotherapy in a PD-L1–positive population was also suggested in previous studies for metastatic ERBB2-positive breast cancer.10,12 The pCR rate of the neoadjuvant taxane-trastuzumab-pertuzumab triplet regimen was 49% in the NeoSphere study6 and 55% in the DAPHNE study,13 which suggests careful patient selection is needed when giving intensified or deintensified treatment. This evidence concerns the gene ERBB2 and breast carcinoma.